olivLaw · US equity research
Anbio Biotechnology NNNN
In Vitro & In Vivo Diagnostic Substances · SIC 2835 · Vertical: In Vitro & In Vivo Diagnostic Substances (SIC 2835)
At the close of 04 Nov 2026, Anbio Biotechnology (NNNN) stock was 3.68 USD (+2.65% on the day), with P/E 25.0 on diluted EPS of 0.15 USD over the last 12 months, beta 0.33, 52-week range 3.13–41.11 USD.
Data as of · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 37.5
- weak (30–45)
- Bollinger (20, 2)
- 2.94 – 4.59
- in the lower half of the band · %B 0.45 · band width 43.7%
- SMA 50 / 200
- 5.23 / 16.89
- downtrend (price < SMA50 < SMA200)
- MACD (12, 26, 9)
- -0.52 / -0.63
- MACD above signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | −23.8% | −1.1% | −22.7 pp | — |
| 3 months | −63.7% | −0.5% | −63.3 pp | — |
| 6 months | −86.2% | +4.4% | −90.6 pp | — |
| Year to date | −87.8% | +12.3% | −100.1 pp | — |
| 1 year | −73.7% | +13.5% | −87.2 pp | −21.1% |
| 3 years | unavailable | +76.4% | unavailable | −58.5% |
| 5 years | unavailable | +63.7% | unavailable | — |
Price returns, dividends excluded.
Quarterly results
ESEF annual reports carry no quarters: the results are annual (below).
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Today's P/E sits at the 0 percentile of its own 1-quarter history (min 204.6, median 204.6, max 204.6; quarters with earnings only).
Fiscal years
| Fiscal year | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | 23.5 m | 6.7 m | 8.2 m | 8.6 m |
| Revenue YoY | unavailable | −71.5% | +21.9% | +5.6% |
| Net income | 10.0 m | 2.3 m | 2.4 m | 6.4 m |
| Net income YoY | unavailable | −77.5% | +5.3% | +169.9% |
| Diluted EPS | 100,112.00 | 0.11 | 0.06 | 0.15 |
| Diluted EPS YoY | unavailable | −100.0% | −46.7% | +162.5% |
| net % | 42.5% | 33.6% | 29.0% | 74.1% |
| Free cash flow | unavailable | unavailable | unavailable | unavailable |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 7.8 m USD
- Financial debt
- unavailable USD
- Net debt
- unavailable USD
- Equity
- 30.2 m USD
- Total assets
- 30.2 m USD
- Debt / equity
- unavailable
- Current ratio
- 344.31x
- ROE
- 27.0%
- ROA
- 26.0%
- FCF margin
- unavailable
Financial statements (source on every figure)
Revenue and net income (USD)
Margins
Income statement · USD
| Line | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|
| Revenue | 23.5 m | 6.7 m | 8.2 m | 8.6 m | SEC (XBRL)· 07 Apr 2026verified |
| Cost of revenue | 11.0 m | 3.4 m | 2.3 m | 1.1 m | SEC (XBRL)· 07 Apr 2026verified |
| Gross profit | 12.6 m | 3.4 m | 5.9 m | 7.5 m | SEC (XBRL)· 07 Apr 2026verified |
| Research & development | 200.0 k | 134.7 k | 454.2 k | 201.3 k | SEC (XBRL)· 07 Apr 2026verified |
| SG&A | 2.2 m | 1.3 m | 3.4 m | 1.6 m | SEC (XBRL)· 07 Apr 2026verified |
| Operating income | 10.2 m | 2.0 m | 2.0 m | 5.8 m | SEC (XBRL)· 07 Apr 2026verified |
| Interest expense | 8.0 k | — | — | — | SEC (XBRL)· 28 Apr 2025verified |
| Pre-tax income | 10.0 m | 2.3 m | 2.4 m | 6.4 m | SEC (XBRL)· 07 Apr 2026verified |
| Income tax | — | 0 | 0 | 0 | SEC (XBRL)· 07 Apr 2026verified |
| Net income | 10.0 m | 2.3 m | 2.4 m | 6.4 m | SEC (XBRL)· 07 Apr 2026verified |
| Diluted EPS | 100,112.00 | 0.11 | 0.06 | 0.15 | SEC (XBRL)· 07 Apr 2026verified |
| Weighted average diluted shares | — | 21.4 m | 42.3 m | 43.7 m | SEC (XBRL)· 07 Apr 2026verified |
Balance sheet · USD
| Line | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|
| Cash | 7.1 m | 9.7 m | 11.8 m | 7.8 m | SEC (XBRL)· 07 Apr 2026verified |
| Receivables | — | 1.9 m | 1.1 m | 3.7 m | SEC (XBRL)· 07 Apr 2026verified |
| Current assets | — | 15.7 m | 18.5 m | 30.2 m | SEC (XBRL)· 07 Apr 2026verified |
| Total assets | — | 15.8 m | 18.9 m | 30.2 m | SEC (XBRL)· 07 Apr 2026verified |
| Accounts payable | — | 827.2 k | 1.6 m | 0 | SEC (XBRL)· 07 Apr 2026verified |
| Current liabilities | — | 993.1 k | 1.7 m | 87.8 k | SEC (XBRL)· 07 Apr 2026verified |
| Total liabilities | — | 993.1 k | 1.7 m | 87.8 k | SEC (XBRL)· 07 Apr 2026verified |
| Equity | 12.5 m † | 14.8 m † | 17.2 m † | 30.2 m † | SEC (XBRL)· 07 Apr 2026verified |
† equity attributable to the parent's shareholders: in these years the issuer no longer reports the total including non-controlling interests.
Cash flow · USD
| Line | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|
| Operating cash flow | 4.4 m | 898.4 k | 2.1 m | -6.7 m | SEC (XBRL)· 07 Apr 2026verified |
| Investing cash flow | -1.5 m | 1.7 m | 337.1 k | -4.2 m | SEC (XBRL)· 07 Apr 2026verified |
| Financing cash flow | — | -42.8 k | -344.6 k | 6.9 m | SEC (XBRL)· 07 Apr 2026verified |
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- indicators available: 5 of at least 6
- score weight coverage: 37.5% of at least 60%
- valuation methods computed: 0 of at least 1
A scoring methodology on indicators and valuation, not investment advice.
Closing price
04 Nov 2026Source: olivLaw, closing series
Market cap: unavailable
Key indicators
Coverage and freshness
Score by group
38% · Insufficient data
Estimated value range
unavailable — no valuation method could be computed
Valuation assumptions are editorial choices, not measured; beta is not measured.
Valuation methods
- DCF (discounted cash flow)unavailable · input data missing
- Peers: EV/EBITDAunavailable · net debt missing: EV cannot be bridged to equity (missing debt is not zero)
- Peers: P/Eunavailable · not enough peers
- Dividend discount (DDM)unavailable · the company pays no dividend: a dividend model needs an explicit initiation assumption
no valuation method could be computed
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Insufficient data
Minimum-evidence gate: indicators available: 5 of at least 6; score weight coverage: 37.5% of at least 60%; valuation methods computed: 0 of at least 1
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | unavailable | unavailable | — |
| Net margin · Quality | 74.1% | 100 (vs peers) | 17% |
| FCF conversion · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | -28.4% | 0 (on a fixed band) | 22% |
| EPS CAGR 3Y · Growth | -98.9% | 0 (on a fixed band) | 22% |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | unavailable | unavailable | — |
| Current ratio · Balance sheet | 344.3x | 100 (on a fixed band) | 11% |
| P/E (TTM) · Valuation | 25.0x | 23 (on a fixed band) | 28% |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | unavailable | unavailable | — |
| Shareholder yield (distributions) · Returns | unavailable | unavailable | — |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet· partial100/100 · 1/3 factors with a value
- Growth0/100 · 2/2 factors with a value
- Quality· partial100/100 · 1/3 factors with a value
- Returns· partialunavailable · 0/2 factors with a value
- Valuation· partial23/100 · 1/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
Anbio Biotechnology (NNNN). Latest full fiscal year: 2025; data up to 2025-12-31.
Figures computed from the financial statements: revenue 8.6 m USD in 2025; YoY growth 5.6%; net margin 74.1%; ROE 27.0%.
Valuation cannot be computed from the available data.
Insufficient data for a verdict (indicators available: 5 of at least 6; score weight coverage: 37.5% of at least 60%; valuation methods computed: 0 of at least 1).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- Net margin: 74.1%
- Current ratio: 344.3x
What contradicts it
- Revenue CAGR 3Y: -28.4%
- EPS CAGR 3Y: -98.9%
- P/E (TTM): 25.0x
Not assessed (insufficient data or a ratio without meaning): ROIC, FCF conversion, Net debt / EBITDA, Interest coverage, EV/EBITDA, FCF yield, Shareholder yield (distributions), Payout ratio (FCF).
Versus the vertical median
In Vitro & In Vivo Diagnostic Substances (SIC 2835) · same industry (4-digit SIC) · compared with 17 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| IDXXIdexx Laboratories Inc | 55.0 bn | 47.1 | 68.9% | 25.4% | +10.4% | −7% / +50% |
| LNTHLantheus Holdings, Inc. | 6.6 bn | 24.5 | 22.2% | 17.7% | +0.5% | +72% / +41% |
| NEOGNeogen Corporation | 2.7 bn | — | -2.7% | -6.3% | −2.7% | +108% / −27% |
| TRIBTrinity Biotech PLC | 2.4 bn | — | — | -51.6% | +8.3% | −80% / −91% |
| CLDXCelldex Therapeutics, Inc. | 2.4 bn | — | -43.9% | -190,220.9% | −78.0% | +11% / −1% |
| NTLAIntellia Therapeutics, Inc. | 1.7 bn | — | -6,424.8% | -672.2% | +16.9% | +37% / −58% |
| QDELQuidelortho Corp | 984.6 m | — | -19.3% | -14.2% | −1.9% | −48% / −79% |
| ACHVAchieve Life Sciences, Inc. | 718.3 m | — | -845.0% | — | unavailable | +43% / +21% |
| MYGNMyriad Genetics, Inc. | 575.8 m | — | -32.5% | -14.0% | −1.6% | −21% / −68% |
| TKNOAlpha Teknova, Inc. | 395.7 m | — | -24.2% | -38.4% | +7.4% | +57% / +261% |
| ICCCImmuCell Corporation | 94.2 m | 138.2 | 2.6% | 2.6% | +4.3% | +114% / +128% |
| IMDXInsight Molecular Diagnostics Inc. | 86.7 m | — | — | -2,955.6% | +115.6% | −57% / −30% |
| BMRABiomerica, Inc. | 8.0 m | — | -113.8% | -115.5% | −16.2% | −27% / −77% |
| CDIOCardio Diagnostics Holdings, Inc. | 4.9 m | — | -75.4% | -44,771.8% | −57.5% | −43% / −97% |
| QCLSQ/C Technologies, Inc. | 3.2 m | — | -155.0% | — | −5.3% | −89% / −100% |
| VNRXVolitionRx Limited | 2.8 m | — | — | -1,043.1% | +40.0% | −97% / −99% |
| VRAXVirax Biolabs Group Ltd | 695.1 k | — | -109.6% | -95,739.2% | −96.0% | −88% / −98% |
| NNNNAnbio Biotechnology | — | 25.0 | 27.0% | 74.1% | +5.6% | −74% / unavailable |
1- and 3-year price returns: for NNNN from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Scenarios are not available. input data missing
AI analysis
The qualitative analysis has not been written for this company yet.
Products, market & competition
The qualitative analysis has not been written for this company yet.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
No news in our archive over the last 180 days.
SEC filings
- Current report (foreign issuer)19 May 2026
- Current report (foreign issuer)27 Apr 2026
- Annual report (foreign issuer)07 Apr 2026
- Current report (foreign issuer)17 Feb 2026
- Current report (foreign issuer)26 Jan 2026
- Current report (foreign issuer)30 Dec 2025
- Current report (foreign issuer)13 Nov 2025
- Annual report (foreign issuer)28 Apr 2025
- Current report (foreign issuer)21 Feb 2025
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.